Literature DB >> 25739989

Tolerance of activated pathogenic CD4+ T cells by transcriptional targeting of dendritic cells.

B de Andrade Pereira1, M Ackermann1, S Chaudhary1, R Vogel1, B Vogt1, C Dresch1, C Fraefel1.   

Abstract

We have recently shown that targeted expression of myelin oligodendrocyte glycoprotein (MOG) to dendritic cells with self-inactivating-lentivirus vectors induces antigen-specific tolerance in naive antigen-specific CD4+ T cells and protects mice from experimental autoimmune encephalomyelitis (EAE). In the present study, we demonstrate that this approach also induces tolerance of activated antigen-specific CD4+ T cells and completely protects mice from passive EAE induction. Tolerance induction did not correlate with the depletion of the preactivated antigen-specific CD4+ T cells. However, upon isolation and in vitro re-stimulation at day 6 after adoptive transfer the MOG-specific CD4+ T cells from the non-tolerized mice produced large amounts of inflammatory cytokines, whereas those from tolerized mice did not. This unresponsiveness correlated with the upregulation of regulatory molecules associated with anergy and regulatory T cells (Tregs). The in vivo depletion of Tregs resulted in EAE susceptibility of the tolerized animals, suggesting that these cells have indeed a role in tolerance induction/maintenance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25739989     DOI: 10.1038/gt.2015.6

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  53 in total

1.  Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion.

Authors:  C Bouneaud; P Kourilsky; P Bousso
Journal:  Immunity       Date:  2000-12       Impact factor: 31.745

2.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

Authors:  Melanie Greter; Frank L Heppner; Maria P Lemos; Bernhard M Odermatt; Norbert Goebels; Terri Laufer; Randolph J Noelle; Burkhard Becher
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

3.  Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.

Authors:  Adam T Hagymasi; Aaron M Slaiby; Marianne A Mihalyo; Harry Z Qui; David J Zammit; Leo Lefrancois; Adam J Adler
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

4.  Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10(+) IFN-γ(+)-producing CD4(+) T cells.

Authors:  Fang Zhou; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

5.  Association of smoking with risk of multiple sclerosis: a population-based study.

Authors:  Sreeram V Ramagopalan; Joshua D Lee; Irene M Yee; Colleen Guimond; Anthony L Traboulsee; George C Ebers; A Dessa Sadovnick
Journal:  J Neurol       Date:  2013-03-02       Impact factor: 4.849

Review 6.  Immunopathogenesis and immunotherapy of multiple sclerosis.

Authors:  Bernhard Hemmer; Stefan Nessler; Dun Zhou; Bernd Kieseier; Hans-Peter Hartung
Journal:  Nat Clin Pract Neurol       Date:  2006-04

7.  Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.

Authors:  Rebecca L Zuvich; Jacob L McCauley; Jorge R Oksenberg; Stephen J Sawcer; Philip L De Jager; Cristin Aubin; Anne H Cross; Laura Piccio; Neelum T Aggarwal; Denis Evans; David A Hafler; Alastair Compston; Stephen L Hauser; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Hum Genet       Date:  2010-01-30       Impact factor: 4.132

8.  CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Authors:  Moa Fransson; Elena Piras; Joachim Burman; Berith Nilsson; Magnus Essand; Binfeng Lu; Robert A Harris; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  J Neuroinflammation       Date:  2012-05-30       Impact factor: 8.322

9.  IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).

Authors:  Antonio Alcina; María Fedetz; Dorothy Ndagire; Oscar Fernández; Laura Leyva; Miguel Guerrero; María M Abad-Grau; Carmen Arnal; Concepción Delgado; Miguel Lucas; Guillermo Izquierdo; Fuencisla Matesanz
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

10.  Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.

Authors:  Michael P Pender; Peter A Csurhes; Corey Smith; Leone Beagley; Kaye D Hooper; Meenakshi Raj; Alan Coulthard; Scott R Burrows; Rajiv Khanna
Journal:  Mult Scler       Date:  2014-02-03       Impact factor: 6.312

View more
  3 in total

Review 1.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

2.  Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance.

Authors:  Kunal H Bhatt; Rajeev Rudraraju; Jeremy F Brooks; Ji-Won Jung; Ryan Galea; James W Wells; Raymond J Steptoe
Journal:  Stem Cell Res Ther       Date:  2017-03-09       Impact factor: 6.832

Review 3.  Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Authors:  Judith Derdelinckx; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.